When evaluating a potential prognostic significance of the EGFR-MAPK axis, results from an in silico analysis of publicly available HNSCC cohorts and immunohistochemically assessed expression levels of activated ERK1/2 and EGFR revealed both markers to impact on clinical outcome in HNSCC. The gene discussed is MAPK3; the disease is head and neck squamous cell carcinoma.